Oncology and Carcinogenesis articles for Germany

Time frame: 1 May 2025 - 30 April 2026

View topic

Count: 488

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
2 0.16
Metallosalphen-Covalent Organic Framework-Based Semiconducting Artificial Enzymes with Radio-Activable Antitumor Immunity for Suppressing Tumor Metastasis and Recurrence 0.12
Peroxidase-Inspired Polyphthalocyanine Networks with Highly Efficient Sonocatalytic Activities for On-Demand Tumor Immunotherapies in Breast Cancers 0.04
1 0.02
Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells 0.02
2 1.26
Light Activated Induction of Cuproptosis in Resistant Cancer Cells Using Polymeric BODIPY Nanoparticles for Photoactivated Chemotherapy 1.00
Immune-Engineered Hydrogels Combat Orthotopic and Metastatic Cancer via Hypoxia-Relieved Photodynamic Therapy and Ferroptotic Cell Death 0.26
2 0.18
NIR-II Photoactivatable Cobalt(III) Nanoparticles for Photoactivated Metal Chemo-Immunotherapy 0.14
Neuroblastoma‐Targeting π‐Conjugated COP Nanostructure with Multiple Enzyme‐Mimetic Actions for Sonochemodynamic Immunotherapies 0.04
1 0.16
Obesity promotes conserved inflammatory and metabolic transcriptional programs in colon tumors: Evidence from mouse models and the ColoCare Study patient cohort 0.16
1 0.10
BRCA1-, BRCA2-, and PALB2-related Fanconi anemia: Scope to expand disease phenotypic features and predict breast cancer risk in heterozygotes 0.10
1 0.83
Identification of a growth-promoting gene cluster in the region 2q24 as a driver of tumorigenesis in childhood hepatoblastoma 0.83
3 2.17
Robust Automated Separation of Circulating Tumor Cells and Cancer-Associated Fibroblasts for Enhanced Liquid Biopsy in Breast Cancer 0.56
Probing Field Cancerization in the Gastrointestinal Tract Using a Hybrid Raman and Partial Wave Spectroscopy Microscope 0.67
Coupling Immunoprecipitation with Multiplexed Digital PCR for Cell-Free DNA Methylation Detection in Small Plasma Volumes of Early-Onset Colorectal Cancer 0.94
6 3.95
Boosting Cancer Chemoimmunotherapy with Mitochondria-Targeting Iridium(III)-Based Immunogenic Oncosis Inducers 0.13
Conditional Stabilization of the Hypoxia‐Inducible Factor HIF1α— Photoswitchable Stapled Peptides Prevent Elongin BC–Mediated Degradation 1.00
Cyclometalating Ligand Affords NIR Absorption in Ruthenium Complexes for Type‐I Photodynamic Therapy 0.07
Interactome Profiling of a Lysine Deacetylase Trapping Probe Library Uncovers Crosstalk Between HDAC6 and NF‐κB Signaling 1.00
Redirecting the Peptide Cleavage Causes Protease Inactivation 0.76
Biaryl Phosphates and Phosphonates as Selective Inhibitors of the Transcription Factor STAT4 1.00
1 0.75
Recombinant Human Neuregulin1‐β1 Significantly Reduces Schwannoma Growth in Mice 0.75
5 1.23
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.17
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.03
Impact of Merging two high-volume Centers on Patient Outcome: 1000 Consecutive Pancreatoduodenectomies. 0.02
Adherence to Multidisciplinary Tumor Board Decisions Determines Long-term Survival in Patients with Hepatocellular Carcinoma. 0.97
Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials. 0.05
2 1.47
A germline IκBα mutation outside the signal reception domain blocks nuclear translocation of NFκB1 and associates with autoinflammation-like features 1.00
Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus 0.47
18 6.65
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.15
Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability 0.03
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia 0.88
Time of day of CAR T-cell infusion and outcomes in large B-cell lymphoma 0.13
Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma 1.00
Menin inhibition with revumenib for iNPM1/i-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study 0.06
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.05
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.05
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.04
CircFUT8 promotes proplatelet formation by interacting with IGF2BP2 and stabilizing TNS1 mRNA in megakaryocytes 0.08
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin 0.02
Clinical presentation, management and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy 0.10
Boosting CAR T-Cell Efficacy by Blocking Proteasomal Degradation of Membrane Antigens 0.91
Iron overload in HFE-related hemochromatosis severely impairs Vδ2+ γδ T-cell homeostasis 1.00
Remission conversion drives outcomes after CAR T-cell therapy for multiple myeloma – A registry analysis from the DRST 1.00
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma. 0.17
Ultrasensitive detection of circulating multiple myeloma cells by next-generation flow after immunomagnetic enrichment 0.03
STING activation improves T-cell-engaging immunotherapy for acute myeloid leukemia 0.97
5 1.50
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.05
Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma 0.05
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study 0.45
Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials 0.05
Mortality after total pancreatectomy in an observational nationwide cohort study 0.90
6 2.25
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma 0.83
RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition 0.02
A stratification system for breast cancer based on basoluminal tumor cells and spatial tumor architecture 0.04
Spatial proteo-transcriptomic profiling reveals the molecular landscape of borderline ovarian tumors and their invasive progression 0.38
CSF1R+ myeloid-monocytic cells drive CAR-T cell resistance in aggressive B cell lymphoma 0.94
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target 0.05
8 3.33
Inhibition of GSK3 and TSC2 Mediates the Oncogenic Activity of AKT in Hepatocellular Carcinoma 0.13
Integrated Single-Nucleus and Spatial Transcriptomics Elucidate Heterogeneity and Hypoxia-Driven Organization of Supratentorial Ependymoma. 1.00
PRDM16 Regulates Prostate Cancer Cell Dormancy and Prevents Bone Metastatic Outgrowth. 0.10
FLT3-ITD Induces CMTM6 and Enhances Immune Escape in Acute Myeloid Leukemia. 1.00
CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer 0.02
Targeting Intracellular Innate RNA-Sensing Systems Overcomes Resistance to CAR T-cell Therapy in Solid Tumors 1.00
Chronic Stress Stimulates Protumor Macrophage Polarization to Propel Lung Cancer Progression 0.03
Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer 0.06
5 1.16
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trial 0.04
Anti-BCMA CAR-T therapy in patients with progressive multiple sclerosis 0.06
A split-site E3 ligase mechanism enables ZNFX1 to ubiquitinate and cluster single-stranded RNA into ubiquitin-coated nucleoprotein particles 0.17
Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia 0.74
Long-term histone lactylation connects metabolic and epigenetic rewiring in innate immune memory 0.15
1 0.02
Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet-induced therapeutic vulnerability in lung cancer 0.02
2 1.57
Histidine methylation via an enzymatic cascade with in situ generation of nucleoside-modified AdoMet analogues 0.57
Red-light excitation of a Ru(ii)–Pt(ii) tetranuclear complex for combined photoactivated chemotherapy and photodynamic therapy 1.00
2 0.44
Light-triggered toll-like receptor activation in a nanoscale metal–organic framework for synergistic PDT and cancer immunotherapy 0.19
Discovery and optimisation of a covalent ligand for TRIM25 and its application to targeted protein ubiquitination 0.25
3 1.06
Targeting Interleukin-8-Mediated Cellular Crosstalk Reverses Hypertrophic Cardiomyopathy and Cardiac Fibrosis in Noonan Syndrome. 0.98
Breast Cancer Reveals Latent BMPR2-Related Susceptibility to Pulmonary Hypertension 0.03
miR-499 in Platelet-Derived Extracellular Vesicles Augments Inflammatory Cell Generation and Cardiac Remodeling After Myocardial Infarction. 0.06
3 1.64
Cohesin and its regulation promote monopolar kinetochore orientation at meiosis I in Arabidopsis 0.50
Extracellular matrix restrains cell-cycle progression by nuclear exclusion of Yorkie in Drosophila 1.00
Polo kinase inhibits protein phosphatase 1 to promote the spindle assembly checkpoint and prevent aneuploidy 0.14
3 1.07
Multi-omic analyses reveal a differential contribution of chromatin-associated PP1 holoenzymes to mitotic exit and G1 re-establishment 0.06
Maternal CENP-C restores centromere symmetry in mammalian zygotes to ensure proper chromosome segregation 0.05
Rbpms2 prevents major cardiac defects in cardiomyocyte-specific Rbpms-deficient mice 0.96
5 1.13
Association Between the PRIMARY Score at Staging Prostate-specific Membrane Antigen Positron Emission Tomography and Overall Survival Among Patients with Newly Diagnosed Prostate Cancer: Findings from the International, Multicenter PROMISE Registry 0.59
Histopathology-based Artificial Intelligence Algorithms for the Prediction of Prostate Cancer Metastasis After Radical Prostatectomy 0.02
Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial 0.03
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma 0.38
Postprogression Survival of Patients with Metastatic Hormone-sensitive Prostate Cancer who Received Darolutamide or Placebo in Combination with Docetaxel and Androgen Deprivation Therapy: Post Hoc Analysis of the Phase 3 ARASENS Trial 0.10
2 1.52
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 0.52
Targeting Mutual Dependence of Phosphatidylinositol-3-Kinase α/δ and Small Ubiquitin-Like Modifier Signaling in Pancreatic Cancer 1.00
1 1.00
ELAV mediates circular RNA biogenesis in neurons 1.00
7 2.42
Molecular and cellular consequences of tumour-autonomous IL-6 signalling in intrahepatic cholangiocarcinoma 0.08
Hereditary chronic pancreatitis induced plasticity cooperates with mutant Kras in early pancreatic carcinogenesis 0.97
Hereditary diffuse gastric cancer spectrum associated with germline iCTNNA1/i loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls 0.10
Comparative risk of high-risk neoplasia after polypectomy among individuals aged below 50 years versus 50 years and older 0.11
Clinical results of an HBV-specific T-cell receptor-T-cell therapy (SCG101) in patients with HBV-related hepatocellular carcinoma treated in an investigator-initiated, interventional trial 0.13
Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential 0.03
Activation of RAS/MEK/ERK signalling drives biliary differentiation in primary liver cancer 1.00
6 0.67
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.07
Targeting mTORC2-Dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma. 0.04
NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway. 0.03
A multicenter dose-defining/expansion phase 1b study of first-line regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma. 0.41
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement. 0.04
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable hepatocellular carcinoma: HIMALAYA phase 3 randomized clinical trial. 0.07
2 1.03
Immune signature-based uncoupling of checkpoint inhibitor efficacy and toxicity 0.03
Polyamines regulate adaptive antitumor immunity by functional specialization of regulatory T cells 1.00
1 0.25
Heavy Alkaline Earth Radiometals for Cancer Theranostics: Coordination and Radiochemistry of Radium-223 and Barium-131 with Kryptofix 22-Based Chelators 0.25
4 0.62
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.06
Geographic analysis and trends in mortality from mesothelioma in Mexico 1998–2022 0.44
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.03
Statins and the risk of gynecological cancer: a Norwegian population-based cohort study 0.08
2 0.15
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.08
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.07
1 0.10
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.10
9 6.49
Genome-wide chromatin profiling reveals a nonlimiting role for RXR in macrophage-like cells stimulated with multiple nuclear receptor agonists 0.09
HSP-1-Specific Nanobodies Alter Chaperone Function in vitro and in vivo 0.15
Minimal Actin Cortices: The αD-Helix of Ezrin’s C-ERMAD Governs F-Actin Binding 1.00
SDF2 and SDF2L1 are essential co-factors of DNAJB11 for Polycystin-1 processing 1.00
The E3 ubiquitin ligase SPRYD3-MYCBP2(PAM) regulates mitotic cell fate and ubiquitination of USP11 to control spindle assembly 1.00
The activity of the EMT suppressor GRHL2 is regulated by SUMOylation 1.00
Conformations of the three gates in Saccharomyces cerevisiae topoisomerase II and their response to DNA, nucleotide, and etoposide 1.00
Functional investigation of the RNA helicase MOV10 with respect to its interplay with factors involved in nonsense-mediated mRNA decay 0.75
SART1 uniquely localizes to spindle poles forming a SART1 cap and promotes spindle pole assembly 0.50
2 1.07
Phosphoproteomic identification of Mos–MAPK targets in meiotic cell cycle and asymmetric oocyte divisions 1.00
Moesin controls cell–cell fusion and osteoclast function 0.07
3 2.02
An Interpretable Machine Learning Model for Predicting Occult Central Lymph Node Metastasis in Papillary Thyroid Cancer 0.05
Machine Learning Prediction of Recurrence in Pediatric Thyroid Cancer: Malignant Endocrine Tumors Cohort Analysis Using XGBoost and SHAP 1.00
Comprehensive Assessment of Multikinase Inhibitor Therapy Outcomes in RAIR-(P)DTC and MTC at a Tertiary Referral Center 0.97
12 3.09
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.63
Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization 0.94
Rho/ROCK signaling and α-Catenin mediate β-Catenin-driven hyperplasia in the adrenal cortex via adherens junctions 0.04
High 4E-BP-1 expression associates with chromosome 8 gain and CDK4/6 sensitivity in Ewing Sarcoma 0.93
Acetyl-CoA carboxylase-1 inhibition increases regulatory T-Cell metabolism and graft-vs-host disease treatment efficacy via mitochondrial fusion 0.09
Personalized treatment in HPV+ oropharynx cancer using genomic adjusted radiation dose 0.04
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.19
PTBP1 variants displaying altered nucleocytoplasmic distribution are responsible for a neurodevelopmental disorder with skeletal dysplasia 0.03
Targeting peroxiredoxin 2 prevents hepatocarcinogenesis in metabolic liver disease models 0.10
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.04
Polybromo 1/vimentin axis dictates tumor grade, epithelial-mesenchymal transition, and metastasis in pancreatic cancer 0.04
TDP-43 dysregulation of polyadenylation site selection is a defining feature of RNA misprocessing in amyotrophic lateral sclerosis and frontotemporal dementia 0.02
34 8.76
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study. 0.04
Tislelizumab Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized, Phase II Trial (EC-CRT-002). 0.05
First-in-Human Study of IL15-Activated Cytokine-Induced Killer Cells After Allogeneic HCT Shows Durable Remission and Serotherapy-Associated Immune Reconstitution in Leukemia. 0.92
Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. 0.09
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.34
Development and Validation of a Computational Histology Artificial Intelligence-Powered Predictive Biomarker for Selection of Chemotherapy in Advanced Pancreatic Cancer. 0.02
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II). 0.25
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study. 0.45
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.04
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial. 0.39
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.05
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.03
Amivantamab Plus Lazertinib in Atypical EGFR-Mutated Advanced Non–Small Cell Lung Cancer: Results From CHRYSALIS-2 0.03
Individual Patient Data Meta-Analysis of Consensus Molecular Subtypes as Biomarkers of First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer. 0.91
Reducing Daunorubicin in Induction Therapy in Children With B-Lineage ALL With Favorable Prognosis: Results of Phase III Trial AIEOP-BFM ALL 2009. 0.33
Colorectal-Specific Radiation Dose and Chemotherapy Risk for Subsequent Colorectal Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study (CCSS) Report. 0.04
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. 0.07
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML. 0.03
Impact of Human Epidermal Growth Factor Receptor 2 in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab or Anti-EGFRs: Exploratory Analysis of Eight Randomized Trials. 0.09
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.10
Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis. 0.71
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. 0.35
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial. 1.00
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study. 0.09
Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas 0.33
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.06
Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial. 0.71
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.03
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients. 1.00
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study. 0.04
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study. 0.05
Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes. 0.04
4 2.01
Liver-X-receptor agonism enhances T cell priming and activation to promote anti-tumor immunity 0.24
NIK-driven IL-23 production by myeloid cells is a key factor in the development of autoimmune inflammation 0.75
Radiotherapy induces YTHDF2 in dendritic cells impairing cross-presentation and T cell function 0.02
RIPK1 autophosphorylation at S161 mediates cell death and inflammation 1.00
1 0.02
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study 0.02
2 0.65
Validation of PARACELSUS score performance for the diagnosis of pyoderma gangrenosum: An international multicenter study with 1403 cases 0.45
Red light photodynamic therapy with 10% aminolevulinic acid gel showed efficacy for treatment of superficial basal cell carcinoma in a randomized, vehicle controlled, double-blind, multicenter phase III study 0.20
3 1.05
MSA-2 Loaded Three-Dimensional Metal Covalent Organic Framework for Synergistic Radiosensitization and Innate Immune Activation 0.04
Autonomous Activation of a Gated Chemiluminescent Photosensitizer Enables Targeted Photodynamic Therapy in Tumor Cells 0.94
Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer 0.07
1 1.00
Alternative Splicing in Mechanically Stretched Podocytes as a Model of Glomerular Hypertension. 1.00
12 2.54
Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer 0.93
Conditional recurrence-free survival after curative esophagectomy: individual patient data analysis of 11 trials 0.05
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.02
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer 0.21
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.03
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials 0.07
Early-detection and prevention effects of screening sigmoidoscopy: evidence from randomized trials revisited 1.00
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.03
Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma 0.01
Genetic predisposition to persistent fatigue after a diagnosis of colorectal cancer 0.11
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.07
2 0.52
A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients 0.13
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy 0.38
7 4.74
A time-resolved atlas of histone modifications during mitotic entry 0.23
The essential co-chaperone Sgt1 regulates client dwell time in the Hsp90 chaperone cycle 0.82
A Leishmania virulence factor harnesses an allosteric kinase switch to regulate its ubiquitin ligase activity 0.88
Ubiquitin precursor with C-terminal extension promotes proteostasis and longevity 1.00
Rapid UPF1 depletion illuminates the temporal dynamics of the NMD-regulated human transcriptome 1.00
A redox switch in p21-CDK feedback during G2 phase controls the proliferation-cell cycle exit decision 0.45
Condensin II activation by M18BP1 0.35
1 0.10
Chemical vs Physical Radioenhancement from TiO2 and Au Nanoparticles to Overcome Hypoxic Radioresistance in X-ray Therapy 0.10
22 6.29
Evolutionary characterization of lung cancer metastasis 0.00
Thymic health and immunotherapy outcomes in patients with cancer 0.01
Multidimensional profiling of heterogeneity in supratentorial ependymomas 0.27
Ageing promotes metastasis via activation of the integrated stress response 0.02
Precancerous niche remodelling dictates nascent tumour persistence 0.24
Ancient co-option of LTR retrotransposons as yeast centromeres 0.25
Individualized mRNA vaccines evoke durable T cell immunity in adjuvant TNBC 0.95
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance 0.71
Progressive coevolution of the yeast centromere and kinetochore 0.63
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance 0.02
Genetic elements promote retention of extrachromosomal DNA in cancer cells 0.06
Lymph node environment drives FSP1 targetability in metastasizing melanoma 0.25
Targeting FSP1 triggers ferroptosis in lung cancer 0.10
Origins of chromosome instability unveiled by coupled imaging and genomics 0.89
Functional synapses between neurons and small cell lung cancer 0.92
A missing enzyme-rescue metabolite as cause of a rare skeletal dysplasia 0.49
NASP modulates histone turnover to drive PARP inhibitor resistance 0.07
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity 0.04
Barcoded viral tracing identifies immunosuppressive astrocyte–glioma interactions 0.09
Glioblastoma-instructed astrocytes suppress tumour-specific T cell immunity 0.09
Radiation-induced amphiregulin drives tumour metastasis 0.06
Activation of lysosomal iron triggers ferroptosis in cancer 0.13
2 1.10
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability 0.15
Fructose-1,6-bisphosphate couples glycolytic activity to cell adhesion 0.95
1 0.13
Drug-controlled CAR T cells through the regulation of cell–cell interactions 0.13
95 44.07
Reprogramming of bacterial virulence by lysine acetylation 1.00
2′--methylation-dependent installation of -methylguanosine in the U6 internal stem loop facilitates efficient spliceosome assembly 0.81
Single cell transcriptional evolution of myeloid leukemia of Down syndrome 0.16
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.18
Recurrent DNA break clusters drive replication-stress-induced copy number variants and genome diversification 1.00
Discovery of an Endonuclease G-inhibitory Ku80-peptide protecting against leukemogenic rearrangements at the MLL breakpoint cluster 1.00
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer 0.31
Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy 0.96
Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination 0.80
Multi-layered molecular profiling informs the diagnosis and targeted therapy of desmoplastic small round cell tumor 0.92
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial 0.84
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.14
HR3/RORα-mediated cholesterol sensing regulates TOR signaling 0.06
Spatial single cell transcriptomic analysis informs tumor developmental hierarchy of DICER1 syndrome related sarcoma 0.08
Phosphorylation of SF3B1 by CDK11 orchestrates spliceosome activation via SNIP1-dependent RES complex recruitment 0.07
Iminium-linked hyperporphyrin covalent organic framework mediates type I photodynamic therapy via a photoredox process 0.05
Proteomic characterization of intrahepatic cholangiocarcinoma identifies risk-stratifying subgroups and EIF4A1 as a therapeutic target 0.89
Maturase K forms a plastidial splicing complex with a neofunctionalized branching enzyme 0.18
NR2F6 deletion revives CAR-T cell function and induces antigen-agnostic immune memory in solid tumors 0.06
First-line modified FOLFOX plus/minus nivolumab and Ipilimumab or FLOT plus nivolumab in advanced gastroesophageal adenocarcinoma: a phase II multi-cohort trial 1.00
Composite SMG5-SMG6 PIN domain formation is essential for NMD 1.00
HIF sustain a transcriptional regulatory circuit of EPAS1 expression in renal clear cell carcinoma 0.92
Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function 0.13
Combined targeted and epigenetic-based therapy enhances antitumor immunity by stabilizing GATA6-dependent MHCI expression in pancreatic ductal adenocarcinoma 0.90
Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression 0.04
NEO-STIM advances personalized neoantigen-specific adoptive T cell therapy 0.03
Modulation of Nudt21 levels reveals dose-dependent roles of alternative polyadenylation in tissue regeneration 0.25
De novo variants in the splicing factor gene are associated with neurodevelopmental disorders 0.03
Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy 0.07
Mechanistic insights into recruitment and regulation of the RNA helicase UPF1 in replication-dependent histone mRNA decay 0.88
WRN structural flexibility showcased through fragment-based lead discovery of inhibitors 0.08
Multi-scale classification decodes the complexity of the human E3 ligome 0.98
Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer 0.44
Kinetochore mutations and histone phosphorylation pattern changes accompany holo- and macro-monocentromere evolution 0.81
Reconstructing the three-dimensional architecture of extrachromosomal DNA with ec3D 0.09
Lack of caspase 8 directs neuronal progenitor-like reprogramming and small cell lung cancer progression 1.00
LncRNA regulates cell size in human and mouse by guiding FOSL2 0.03
G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients 1.00
Fragment-based discovery enables direct targeting of the melanoma oncogene MITF 0.03
Predictive models of melanoma metastasis based on dermatoscopy in an international retrospective human reader study 0.06
A JAK/STAT-Pdk1-S6K axis bypasses systemic growth restrictions to promote regeneration 1.00
Single cell mapping identifies a distinct platelet-phenotype in psoriatic type III inflammation 0.76
Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations 0.05
Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies 0.15
MCL1 modulates mTORC1 signaling to promote bioenergetics and tumorigenesis 0.53
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis 0.09
An inflammatory T-cell-stromal axis contributes to hematopoietic stem/progenitor cell failure and clonal evolution in human myelodysplastic syndrome 0.11
Bidirectional communication between nucleotide and substrate binding sites in a type IV multidrug ABC transporter 0.44
LUBAC modulates CBM complex functions downstream of TRAF6 in T cells 0.94
Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma 0.04
Astrocytic-OTUD7B ameliorates murine experimental autoimmune encephalomyelitis by stabilizing glial fibrillary acidic protein and preventing inflammation 0.96
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes 0.74
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry 0.07
Stabilizing a mammalian RNA thermometer confers neuroprotection in subarachnoid hemorrhage 0.28
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity 0.03
Selective ubiquitination of drug-like small molecules by the ubiquitin ligase HUWE1 1.00
Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing 0.04
Structural basis of adhesin Fap2 interaction with receptors on cancer and immune cells 1.00
Hepatitis C virus NS3 helicase contributes to (−) strand RNA synthesis 0.60
ALS/FTD-linked TBK1 deficiency in microglia induces an aged-like microglial signature and drives social recognition deficits in mice 0.09
Patient-derived tumoroids from CIC::DUX4 rearranged sarcoma identify MCL1 as a therapeutic target 0.12
Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition 0.04
The bispecific innate cell engager AFM28 eliminates CD123 leukemic stem and progenitor cells in AML and MDS 1.00
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.03
Bioinspired ruthenium-manganese-oxygen complex for biocatalytic and radiosensitization therapies to eradicate primary and metastatic tumors 0.08
Chromatin retained lncRNA integrates ABA and DOG1 signalling pathways to enhance Arabidopsis seeds dormancy 0.08
Cross-species comparison reveals therapeutic vulnerabilities halting glioblastoma progression 0.92
Pre-mRNA processing factors differentially impact coordination between co-transcriptional cleavage and transcription termination 0.06
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.11
Structure and mechanism of the RalGAP tumor suppressor complex 1.00
Allosteric activation of the SPRTN protease by ubiquitin maintains genome stability 0.89
Notch activity is modulated by the aGPCR Latrophilin binding the DSL ligand in C. elegans 0.88
Structure of a transcribing Pol II-DSIF-SPT6-U1 snRNP complex 0.56
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial 0.02
Interdependence of Pasha and Drosha for localization and function of the Microprocessor in C. elegans 0.17
Role of stem-like cells in chemotherapy resistance and relapse in pediatric T-cell acute lymphoblastic leukemia 0.77
The mitochondrial methylation potential gates mitoribosome assembly 0.19
Constitutive expression of the transcriptional co-activator IκBζ promotes melanoma growth and immunotherapy resistance 0.98
A macrophage-predominant immunosuppressive microenvironment and therapeutic vulnerabilities in advanced salivary gland cancer 0.96
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence 0.03
ELMO2 is an essential regulator of carotid artery development 1.00
CEACAM1 as a mediator of B-cell receptor signaling in mantle cell lymphoma 0.05
HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity 0.03
Interplay of kinetochores and catalysts drives rapid assembly of the mitotic checkpoint complex 1.00
Alveolar epithelial and vascular CXCR2 mediates transcytosis of CXCL1 in inflamed lungs 0.87
A searchable atlas of pathogen-sensitive lncRNA networks in human macrophages 1.00
HIV status alters immune cell infiltration and activation profile in women with breast cancer 0.53
Dual Ribosome Profiling reveals metabolic limitations of cancer and stromal cells in the tumor microenvironment 0.90
Transcriptional and epigenetic rewiring by the NUP98::KDM5A fusion oncoprotein directly activates CDK12 0.05
Wnt/β-catenin activation by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary basal cell adenoma 0.11
ANP32E drives vulnerability to ATR inhibitors by inducing R-loops-dependent transcription replication conflicts in triple negative breast cancer 0.04
A FAN1 point mutation associated with accelerated Huntington’s disease progression alters its PCNA-mediated assembly on DNA 0.42
Genomic landscape of diffuse glioma revealed by whole genome sequencing 0.02
mTORC1 cooperates with tRNA wobble modification to sustain the protein synthesis machinery 0.75
A key residue of the extracellular gate provides quality control contributing to ABCG substrate specificity 0.25
16 2.29
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.16
Systematic analysis of snRNA genes reveals frequent variants in dominant and recessive developmental and epileptic encephalopathies 0.13
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.05
CDK4/6 inhibition mitigates chemotherapy-induced expansion of -mutant clonal hematopoiesis 0.03
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types 0.13
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.04
Patterns of hypermutation shape tumorigenesis and immunotherapy response in mismatch-repair-deficient glioma 0.09
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations 0.80
Transcription factor switching drives subtype-specific pancreatic cancer 0.19
Rapid epigenomic classification of acute leukemia 0.09
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis 0.02
Tamoxifen induces PI3K activation in uterine cancer 0.01
Temporal genomic dynamics shape clinical trajectory in multiple myeloma 0.34
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A 0.05
Phylogenetic inference reveals clonal heterogeneity in circulating tumor cell clusters 0.02
Dominant variants in major spliceosome U4 and U5 small nuclear RNA genes cause neurodevelopmental disorders through splicing disruption 0.14
1 0.58
A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma 0.58
2 0.27
Restoring the tumour mechanophenotype of vocal fold cancer reverts its malignant properties 0.04
Cell viscosity influences haematogenous dissemination and metastatic extravasation of tumour cells 0.23
27 5.77
Isatuximab, carfilzomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma: a randomized phase 3 trial 0.07
Gotistobart or docetaxel in metastatic squamous non-small cell lung cancer: stage 1 of the randomized phase 3 PRESERVE-003 trial 0.08
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.17
Ipilimumab and nivolumab followed by chemoradiotherapy as bladder-sparing treatment in muscle-invasive bladder cancer: a phase 2 trial 0.02
Bispecific T cell engagers for treatment-refractory autoimmune connective tissue diseases 1.00
Anti-CD19 CAR T cells for pediatric patients with treatment-refractory autoimmune diseases 0.27
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.08
Global and regional cancer burden attributable to modifiable risk factors to inform prevention 0.01
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial 0.01
Neoadjuvant ipilimumab plus nivolumab in melanoma: 5-year survival and biomarker analysis from the phase 2 PRADO-trial 0.00
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma 0.29
Soluble MAdCAM-1 as a biomarker in metastatic renal cell carcinoma 0.02
CD19 CAR-T cells for treatment-refractory autoimmune diseases: the phase 1/2 CASTLE basket trial 0.86
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial 0.89
Macrovascular tumor infiltration and circulating tumor cell cluster dynamics in patients with cancer approaching the end of life 0.11
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.04
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.05
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial 1.00
Perioperative IDH inhibition in treatment-naive IDH-mutant glioma: a pilot trial 0.06
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.04
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.31
Peri-operative atezolizumab in early-stage triple-negative breast cancer: final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial 0.10
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial 0.04
Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: the randomized phase 3 CREST trial 0.10
Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer 0.06
1 0.04
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape 0.04
4 2.92
UBA6 specificity for ubiquitin E2 conjugating enzymes reveals a priority mechanism of BIRC6 0.17
Conformational plasticity of a BiP–GRP94 chaperone complex 1.00
TRIP12 structures reveal HECT E3 formation of K29 linkages and branched ubiquitin chains 0.75
Chimeric deubiquitinase engineering reveals structural basis for specific inhibition of the mitophagy regulator USP30 1.00
1 1.00
Inducible gene deletion reveals essentiality of protein kinases and a septation initiation network in Candida albicans 1.00
1 0.10
Childhood cancer in Sweden during the COVID-19 pandemic: Temporal patterns in incidence and survival in a nationwide register-based cohort study. 0.10
19 7.13
DARPins as pan-reactivators of temperature-sensitive p53 cancer mutants 0.81
mtHsp70 chaperone converts mitochondrial proteostasis stress into impaired protein import 1.00
Microglial fructose metabolism is essential for glioblastoma growth 0.03
E2 variants for probing E3 ubiquitin ligase activities 0.80
Pharmacologic reversion of Merkel cell carcinoma via CBP/p300 inhibition 0.40
Control of renal calcium permeability via a tight junctional claudin switch 0.83
The liver talks back: NPY orchestrates attraction of cancer cells and CHK2-dependent clonogenicity in the metastatic niche 0.87
Citrullination negatively regulates the functions of the p53 protein and opposes its ubiquitination and degradation 0.09
Functional spectrum of USP7 pathogenic variants in Hao–Fountain syndrome: Insights into the enzyme’s activity, stability, and allosteric modulation 0.18
The activity and expression of adenylosuccinate lyase were reduced during modern human evolution, affecting brain and behavior 0.15
Neutron and time-resolved X-ray crystallography reveal the substrate recognition and catalytic mechanism of human Nudix hydrolase MTH1 0.18
Inactivation of PI3K-C2α deregulates cell death pathways and sensitizes to endotoxic shock 0.20
The WWP1–JARID1B axis sustains acute myeloid leukemia chemoresistance 0.05
The oncogene SLC35F2 is a high-specificity transporter for the micronutrients queuine and queuosine 0.11
Disruption of constitutive CXCR4 oligomers impairs oncogenic properties in lymphoid neoplasms 0.09
Neuronal ALKAL2 and its ALK receptor contribute to the development of colitis-associated colorectal cancer 0.04
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity 0.04
<atl>The tumor suppressor RASSF8: A WAVE interaction partner controlling migration and cohesion of invasive border cells in iDrosophila/i</atl> 1.00
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency 0.25
4 3.20
Transarterial Radioembolization: Medical Staff Dosimetry for 90Y-Resin, 90Y-Glass, and 166Ho-PLLA Microspheres. 1.00
False-Positive Recall and False-Positive Biopsy Rates in Mammography Screening: A TOSYMA Trial Subanalysis. 1.00
Cancer Detection in Breast MRI Screening via Explainable AI Anomaly Detection. 0.20
Intraindividual Comparison of Ultrafast versus Standard Two-dimensional Dynamic Contrast-enhanced Breast MRI. 1.00
3 0.20
Lymphoid tissue chemokines limit priming duration to preserve CD8+ T cell functionality 0.06
Mechanisms linking cytoplasmic decay of translation-defective mRNA to transcriptional adaptation 0.06
IDH-mutant gliomas arise from glial progenitor cells harboring the initial driver mutation 0.08
12 6.87
KLF5 controls subtype-independent highly interactive enhancers in pancreatic cancer to regulate cell survival 0.79
The accessory adapters FAF1, FAF2, and UBXN7 accelerate proteasomal degradation by increasing prior p97-mediated substrate unfolding 1.00
Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression 0.63
Systemically inducing trained immunity overcomes solid tumors’ immunosuppressive microenvironment 0.01
The BUB1 and BUBR1 paralogs scaffold the kinetochore fibrous corona 1.00
Selective targeting of TBXT with DARPins identifies regulatory networks and therapeutic vulnerabilities in chordoma 0.71
M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development 0.07
Plant defense-directed discovery of a natural anti-psoriasis agent targeting GAPDH 0.10
TP53 missense–specific transcriptional plasticity drives resistance against cell cycle inhibitors in pancreatic cancer 0.93
PET-based immunomapping of intratumoral CD4+ cells to monitor acquired resistance to checkpoint inhibitors 0.73
CD8+ T cell–derived CD40L mediates noncanonical cytotoxicity in CD40-expressing cancer cells 0.85
Interleukin-4 modulates type I interferon to augment antitumor immunity 0.06
4 1.61
Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat 0.99
Lymphotoxin alpha eradicates acute myeloid leukemia and simultaneously promotes healthy hematopoiesis in mice 0.52
PD-1–targeted cis-delivery of an IL-2 variant induces a multifaceted antitumoral T cell response in human lung cancer 0.03
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer 0.07
14 6.63
Microtubule end stabilisation by cooperative oligomers of Ska and Ndc80 complexes 0.08
Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer 0.95
M18BP1 valency and a distributed interaction footprint determine epigenetic centromere specification in humans 1.00
Homeostatic control of energy metabolism by monocyte-derived macrophages 0.05
The transaminase-ω-amidase pathway senses oxidative stress to control glutamine metabolism and α-ketoglutarate levels in endothelial cells 0.89
Concurrence of mutations modulates oncogenesis in glioneuronal tumors 0.05
Nucleosome interaction of the CPC secures centromeric chromatin integrity and chromosome segregation fidelity 0.27
Functional landscape of ubiquitin linkages couples K29-linked ubiquitylation to epigenome integrity 0.25
TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence 0.02
Fusobacterium nucleatum interacts with cancer-associated fibroblasts to promote colorectal cancer 0.06
mTORC1 senses glutamine and other amino acids through GCN2. 1.00
Oligomerised RIPK1 is the main core component of the CD95 necrosome 1.00
The Spc105/Kre28 complex promotes mitotic error correction by outer kinetochore recruitment of Ipl1/Sli15 0.95
Annexin A5 controls VDAC1-dependent mitochondrial Ca2+ homeostasis and determines cellular susceptibility to apoptosis 0.05
1 0.25
Purinosome Unmasked: Exploring the Molecular-Scale Structure of a Purinosome Complex In Silico 0.25
9 0.47
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.05
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.05
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.06
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.05
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study 0.05
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial 0.07
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial 0.04
23 4.33
Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial 0.10
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.06
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.05
Molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer (PORTEC-4a): results of a randomised, open-label, phase 3, multicentre, non-inferiority trial 0.10
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.10
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.07
A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group 0.26
Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials 0.72
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study 0.01
Artificial intelligence and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA): an international, paired, non-inferiority, confirmatory, observational study 0.07
Effectiveness of NELSON versus PLCOm2012 lung cancer screening eligibility criteria in Germany (HANSE): a prospective cohort study 1.00
Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial 0.05
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study 0.18
Analysis of TERT association with clinical outcome in meningiomas: a multi-institutional cohort study 0.10
The effect of TERT promoter mutation on predicting meningioma outcomes: a multi-institutional cohort analysis 0.16
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.05
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.05
Cabozantinib plus atezolizumab in metastatic prostate cancer (CONTACT-02): final analyses from a phase 3, open-label, randomised trial 0.05
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAF V600E or BRAF V600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study 0.05
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study 0.06
Chemotherapy-free neoadjuvant pembrolizumab combined with trastuzumab and pertuzumab in HER2-enriched early breast cancer (WSG-KEYRICHED-1): a single-arm, phase 2 trial 0.97
17 1.22
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.21
Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer 0.09
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer 0.12
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer 0.05
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer 0.07
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.05
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer 0.10
European Study of Prostate Cancer Screening — 23-Year Follow-up 0.01
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.03
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer 0.06
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.02
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.09
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.04
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.11
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.08
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.07
1 0.61
Ubiquitin-dependent proteolysis of KNL2 driven by APC/CCDC20 is critical for centromere integrity and mitotic fidelity 0.61
1 0.43
Increase in second primary lung cancers in a nation-wide cohort study from Sweden 0.43

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.